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LETTERS TO THE EDITOR
Lack of Association Between NOD2 3020InsC Frameshift
Mutation and Psoriasis
To the Editor:
Multiple susceptibility loci have been reported for psoriasis (Capon
et al, 2000), with the strongest evidence for linkage being found
within the major histocompatibility complex (MHC) on chromo-
some 6p21.3 (Balendran et al, 1999; Nair et al, 2000). Our genome-
wide scan for psoriasis susceptibility identi®ed, in addition to
chromosome 6, suggestive evidence for linkage to chromosomes
16, 17, and 20 (Nair et al, 1997). The chromosome 16 locus maps
to a con®rmed susceptibility locus for Crohn's disease (CD) (Rioux
et al, 2000). Because CD patients have a 7-fold greater relative risk
for development of psoriasis (see Nair et al, 1997), it is conceivable
that CD and psoriasis might share a common genetic origin.
Recently, some of us (Ogura et al, 2001) and others (Hampe et al,
2001; Hugot et al, 2001) reported that premature truncation of the
NOD2 gene confers susceptibility in a subset of CD patients, due to
an insertion polymorphism (3020insC) in one of the leucine rich
repeat regions (LRR). The product of the NOD2 gene activates
NF-kB in response to bacterial products, and the 3020insC
mutation leads to altered NF-kB responses (Ogura et al, 2001).
Corticosteroids and sulfasalazine inhibit NF-kB signaling, and both
drugs are effective in psoriasis and CD (Gupta et al, 1990; Thiele et
al, 1999; Weber et al, 2000). TNF-a stimulates NF-kB signaling
(Hsu et al, 1995) and TNF-a levels are markedly elevated in both
diseases (MacDonald et al, 1990; Ettehadi et al, 1994). Moreover,
neutralizing anti-TNF-a antibodies are effective in both diseases
(Baert et al, 1999; Chaudhari et al, 2001). Thus, NOD2 appears to
be an attractive candidate gene for psoriasis via NF-kB signaling. As
an initial test of this hypothesis, we examined whether the
3020insC polymorphism is associated with susceptibility to psor-
iasis, and whether association could be demonstrated to a
microsatellite marker mapping to the immediate vicinity of NOD2.
The study cohort consisted of 520 analyzable families of various
structures. Of these families, 499 (95.8%) were of Caucasian
descent. Ascertainment criteria and genotyping methods have been
described (Nair et al, 1995). A 126±128 bp DNA segment
containing the 3020insC variant was ampli®ed using the ¯anking
primers CCAGGTTGTCCAATAACTGCATC and
GGTTCGGAGAGCTAAAACAGGC. These primers were se-
lected from the genomic NOD2 sequence (GenBank accession
number AC007728) using MacVector. Allele sizes were deter-
mined by reference to the common 127 bp allele. In addition, 481
of the 520 families were typed for D16S3136, which has been
mapped to within 30 kb of the NOD 2gene (Hugot et al, 2001).
Data were analyzed by means of the biallelic transmission
disequilibrium test (TDT) (Spielman et al, 1993), and/or the
general pedigree disequilibrium test (PDT) using the PDT-average
statistic (Martin et al, 2000, 2001). We extended the PDT method
to include dyads (one affected child and one parent), as suggested
by Martin et al. The PDT analysis was conditioned for the presence
or absence of MHC risk alleles by binary weighting, assigning a
weight of 1 if at least one affected individual in the pedigree carried
a risk haplotype in the MHC, and 0 otherwise. MHC risk
haplotypes were determined by cluster analysis of a 34 marker
MHC haplotype followed by TDT analysis of each cluster, as
previously described (Nair et al, 2000). Alternatively, PDT analysis
was conditioned for early age of onset by analyzing only those
families whose affected members had a median age of onset of 25 y
or less.
A fragment of 128 nt representing the 3020insC allele occurred
at a genotype frequency of 2.84% among all founder chromosomes
(54 of 1902), of 2.79% (43 of 1540) among unaffected founder
chromosomes, of 2.63% (9 of 342) among affected founder
chromosomes, and of 2.80% among proband chromosomes (31
of 1108). The allele frequency of 2.84% in founder chromosomes is
similar to those reported for unaffected, unrelated controls in two
recent genetic studies of NOD2 in CD [2% (Hugot et al 2001) and
4% (Ogura et al 2001)]. The transmitted:nontransmitted ratio for
3020insC (45.5%) was lower than that observed for the wild-type
allele (56.5%), and the p values obtained for the 3020insC allele
were not signi®cant (biallelic TDT p value = 0.78, biallelic PDT-
average p value = 0.39). Of note, we identi®ed four occurrences of
a 126 nt fragment, the molecular nature of which remains to be
determined. One individual was homozygous for the 3020insC
allele. This was consistent with the expected frequency of 1.8
individuals based on an allele frequency of 2.8% and a sample size of
2320. This individual was over 60 y old, unaffected with psoriasis,
and had no personal or family history of in¯ammatory bowel
disease. Taken together, these data provide no support for
involvement of the 3020 insC of NOD2 in the genetic etiology
of psoriasis. Sequencing of the NOD2 coding region identi®ed 30
missense variants in the NOD2 gene in CD-affected individuals,
only two of which were present in unaffected controls (Hugot et al,
2001). Before a causative role for the NOD2 gene in psoriasis can
be de®nitively excluded, it will be necessary to test psoriatic
patients for multiple possible mutations in the NOD2 gene.
In addition to 3020 InsC, two other variants of the NOD2 gene
have been shown in linkage disequilibrium with CD (Hugot et al,
2001; Ogura et al, 2001). If one or a few NOD2 alleles other than
3020insC played a major role in psoriasis, one might expect to
detect linkage disequilibrium in ¯anking microsatellite markers,
provided that they resided close enough to the gene. Based on a
recent examination of 19 randomly selected genomic regions,
linkage disequilibrium in a Caucasian population similar to our
own typically extended 60 kb from common alleles (Reich et al,
2001). We typed a microsatellite marker, D16S3136, that maps to
within 30 kb of NOD2 and would therefore be likely to display
linkage disequilibrium with NOD2. Uncorrected PDT average p
values for D16S3136 were 0.072 across all pedigrees, 0.028 in early
onset pedigrees, 0.054 in pedigrees that contain the MHC risk
haplotype (Nair et al 2000), and 0.69 in pedigrees that do not
contain the MHC risk haplotype. After necessary correction for
four tests, none of these p values achieve statistical signi®cance at
the p = 0.05 level.
Our prior linkage results indicative of a 16q locus (Nair et al,
1997) would be expected to occur once in the course of a genome
scan by chance alone (Lander and Kruglyak, 1995). Thus far, no
publications have independently con®rmed this putative locus.
Manuscript received July 18, 2001; revised August 23, 2001; accepted for
publication September 13, 2001
Reprint requests to: Dr. James T. Elder, 3312 Cancer Center and
Geriatric Center Building, 1500 E. Medical Center Drive, University of
Michigan, Ann Arbor, MI 48109±0932. Email: jelder@umich.edu
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
1671
Thus, even though the D16S3136 p values we obtained did not
reach statistical signi®cance, they are of interest because they
provide limited evidence for possible linkage disequilibrium at this
locus. In evaluating these data, it is important to consider that only
a limited subset of psoriatic patients may carry disease-predisposing
NOD2 variants (i.e., genetic heterogeneity) and that multiple allelic
variants of NOD2 might predispose to psoriasis (i.e., allelic
heterogeneity). Either of these situations would be expected to
weaken the statistical evidence for linkage disequilibrium.
Additional, con®rmatory studies will be required in order to
determine whether the clinical concomitance of psoriasis and CD is
due to the existence of one or more disease alleles at NOD2.
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XP43TO, Previously Classi®ed as Xeroderma Pigmentosum
Group E, Should be Reclassi®ed as Xeroderma Pigmentosum
Variant
To the Editor
Xeroderma pigmentosum (XP), a rare autosomal recessive disease
characterized by clinical and cellular hypersensitivity to ultraviolet
(UV) light (Cleaver and Kraemer, 1995), has been classi®ed into
eight genetic groups [A±G, and variant (V)]. XP-E (OMIM no.
278740) was reported to have biochemical heterogeneity regarding
a damage speci®c DNA binding (DDB) activity (Kataoka and
Fujiwara, 1991; Keeney et al, 1992): some strains lacked DDB
activity and were termed Ddb± XP-E, whereas others had activity
and were termed Ddb+ XP-E. After reinvestigating three Ddb+
XP-E cell strains, we recently reported that each had been
misclassi®ed, and based on their phenotypes after UV-irradiation
(unscheduled DNA synthesis, recovery of RNA synthesis, and
recovery of replicative DNA synthesis in the presence and absence
of caffeine) we tentatively reclassi®ed them as XP-F (OMIM no.
278760, XP89TO), XP-V (OMIM no. 278750, XP43TO), and
ultraviolet±sensitive syndrome (OMIM no. 600630, XP24KO)
strains (Itoh et al, 2000a). We therefore supported the tentative
proposal of Cleaver et al (1999) that mutations in the DDB2 gene
should be solely responsible for XP-E (Itoh et al, 2000a; Nichols
et al, 2000).
As the assignment of XP43TO as XP-V was based upon the
recovery of replicative DNA synthesis in the presence of caffeine,
we have analyzed the XP43TO for mutations in the XPV gene.
The XPV gene codes for DNA polymerase h (Johnson et al, 1999;
Masutani et al, 1999), an inducible, damage bypass DNA
polymerase (Yamada et al 2000). RT-PCR products from base
pairs 110±2410 of the XPV cDNA from XP43TO cells showed a
broad band compared with the products from normal Turu cells
(RT-PCR1, Fig 1a). This broadening was not seen, however, for
products from base pairs 898±2416 (RT-PCR2, Fig 1a). Thirty-
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